Compare HQI & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HQI | BDTX |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | United States | United States |
| Employees | 75000 | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 180.1M | 171.9M |
| IPO Year | 2008 | 2020 |
| Metric | HQI | BDTX |
|---|---|---|
| Price | $13.89 | $1.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $13.00 | $9.67 |
| AVG Volume (30 Days) | 7.0K | ★ 732.6K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | 73.08 | ★ 130.71 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $30,640,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.46 | N/A |
| P/E Ratio | $116.45 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.38 | $1.60 |
| 52 Week High | $14.54 | $4.94 |
| Indicator | HQI | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 47.59 |
| Support Level | $12.03 | $1.76 |
| Resistance Level | $13.42 | $1.90 |
| Average True Range (ATR) | 0.66 | 0.09 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 31.53 | 61.82 |
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.